A novel proteomic technique to identify new diagnostic biomarkers for malignant pleural mesothelioma: a feasibility study. Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease Year: 2021
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions Source: Eur Respir J 2013; 41: 18-24 Year: 2013
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment Source: Eur Respir Rev 2016; 25: 472-486 Year: 2016
The reliability of the cytological diagnosis malignant mesothelioma Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Molecular epidemiology in non small cell lung cancer (NSCLC) tumors: implication of gender and histological features Source: Eur Respir J 2006; 28: Suppl. 50, 335s Year: 2006
Potential prognostic factors in typical and atypical carcinoid tumours of the lung - immunhistochemical investigations Source: Eur Respir J 2001; 18: Suppl. 33, 229s Year: 2001
Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis Source: Eur Respir Rev, 30 (162) 210057; 10.1183/16000617.0057-2021 Year: 2021
Patient derived pleural mesothelioma cell lines, can be used as tools, to guide patient stratification Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019
MAdL: A new diagnostic marker for adenocarcinomas Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Hyaluronan: A novel sputum marker for the screening and diagnosis of lung cancer patients Source: Annual Congress 2012 - Early detection of lung cancer Year: 2012
Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation Source: Eur Respir J, 51 (3) 1800153; 10.1183/13993003.00153-2018 Year: 2018
Cytology in differential diagnosis of histological types of NSCLC Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Optimal diagnosis and treatment of malignant pleural disease: challenging the guidelines Source: Eur Respir Monogr 2020; 87: 138-154 Year: 2020
Does the age affect the diagnostic yield of different biomarkers in differentiation between tuberculous and non-tuberculous pleural effusions? Source: International Congress 2017 – Human susceptibility to tuberculosis Year: 2017
Is comorbidity a good prognostic factor for malignant pleural mesothelioma? Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
Time in lung cancer diagnosis and its prognostic implication Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018
Diagnostic usefulness of C reactive protein levels in pleural effusions of malignant and non malignant origin Source: Eur Respir J 2007; 30: Suppl. 51, 431s Year: 2007